Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 6/20 | 0.41 |
| ▸ | FDPS | P14324 | 9/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368059 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL5035850 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL8176550 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL5497444 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL1410606 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL424188 | 0.97 | FDPS (0.38) | GGPS1FDPSSMPD1CES2LPAR1 | |
| SCHEMBL1410618 | 0.90 | — | — | |
| SCHEMBL8906809 | 0.88 | FAAH (0.50) | — | |
| SCHEMBL10530613 | 0.81 | FDPS (0.30) | FDPS | |
| SCHEMBL7722417 | 0.80 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220258-A1 | ORAL DOSAGE FORM WITH SURFACE DELIVERY OF ACTIVE AGENT | ENTREGA INC. | 2021-07-22 | — | — | US | claimed |
| WO-2020072729-A1 | ORAL DOSAGE FORM WITH SURFACE DELIVERY OF ACTIVE AGENT | ENTREGA INC. (US) | 2020-04-09 | — | — | WO | claimed |
| US-20200030242-A1 | ORAL DOSAGE FORM WITH DRYING AGENT FOR DELIVERY OF ACTIVE AGENT | ENTREGA INC. | 2020-01-30 | — | — | US | claimed |
| US-20180185440-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERY OF BREMELANOTIDE | NOVEN PHARMACEUTICALS, INC. (US) | 2018-07-05 | — | — | US | claimed |
| EP-0662965-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1995-07-19 | — | — | EP | claimed |
| US-5321031-A | Treating cardiovascular disorders | SCHERING CORPORATION (US) | 1994-06-14 | — | — | US | claimed |
| WO-1994006784-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | claimed |
| WO-2023215228-A1 | ORAL DOSAGE FORM WITH IONICALLY CHARGEABLE HYDROGEL FOR DELIVERY OF ACTIVE AGENT | ENTREGA INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230093875-A1 | IONIC LIQUIDS FOR INTERNAL DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-03-30 | — | — | US | disclosed |
| US-20230040805-A1 | IONIC LIQUIDS FOR INTERNAL DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-09 | — | — | US | disclosed |
| US-11446253-B2 | Ionic liquids for internal delivery | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210220258-A1 | ORAL DOSAGE FORM WITH SURFACE DELIVERY OF ACTIVE AGENT | ENTREGA INC. | 2021-07-22 | — | — | US | disclosed |
| EP-3709974-A1 | IONIC LIQUIDS FOR INTERNAL DELIVERY | President And Fellows Of Harvard College (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-1153526-A | Concentrated cleaner compositions capable of viscosity increase upon dilution | MINNESOTA MINING & MFG (US) | 1997-07-02 | — | — | CN | disclosed |
| US-5607931-A | AMIDES | SCHERING CORPORATION (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0662965-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1995-07-19 | — | — | EP | disclosed |
| US-5326762-A | Heterocyclic substituted amides | SCHERING CORPORATION (US) | 1994-07-05 | — | — | US | disclosed |
| US-5321031-A | Treating cardiovascular disorders | SCHERING CORPORATION (US) | 1994-06-14 | — | — | US | disclosed |
| WO-1994006784-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
| US-5149709-A | Treatment of atherosclerosis | SCHERING CORPORATION (US) | 1992-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040805-A1 | IONIC LIQUIDS FOR INTERNAL DELIVERY | PNLIP, LIPA, CEL | GGPS1 3459/4885FDPS 4491/4885TSHR 2333/4885 |
| US-11446253-B2 | Ionic liquids for internal delivery | PNLIP, LIPA, CEL | GGPS1 3459/4885FDPS 4491/4885TSHR 2333/4885 |
| US-20180185440-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERY OF BREMELANOTIDE | VIP, MC2R, SLC10A2 | GGPS1 3037/4885FDPS 4114/4885TSHR 677/4885 |
| US-20210220258-A1 | ORAL DOSAGE FORM WITH SURFACE DELIVERY OF ACTIVE AGENT | SI, FABP2, SLC10A2 | GGPS1 4752/4885FDPS 4072/4885TSHR 2163/4885 |
| US-20230093875-A1 | IONIC LIQUIDS FOR INTERNAL DELIVERY | PNLIP, LIPA, CEL | GGPS1 3459/4885FDPS 4491/4885TSHR 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.